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Background: Comorbidity of migraine with anxiety and depression may play a role in the link between migraine
and obesity. We examined the moderating and mediating roles of ghrelin in the relationship between depression
(and anxiety) and body weight in newly diagnosed migraineurs.
Methods: Participants were 63 newly diagnosed migraine patients (using the ICHD-II criteria) and 42 healthy volunteers.
Body mass index (BMI) was calculated by measuring height and weight. Ghrelin was assessed at fasting. Depression was
assessed with the Hamilton Depression scale, and anxiety with the Hamilton Anxiety scale.
Results: The data did not support the mediating role of ghrelin in the relationship between depression (or anxiety) and
BMI for either the migraine or the control group. The interaction between ghrelin and depression as well as anxiety was
significant for the migraine group, but not for the control group. Depressed (or anxious) migraineurs had a positive
association between ghrelin and BMI, whereas for the non-depressed (or non-anxious) migraineurs this association was
negative.
Conclusions: Depression and anxiety moderated the effect of ghrelin on BMI for migraineurs. Management of anxiety
and depression might be regarded as part of migraine treatment.
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Migraine is a recurrent neurovascular disorder with
moderate to severe throbbing and mostly unilateral
headache with or without photo-phonophobia and nau-
sea [1]. The pathophysiology of migraine is not fully
understood. However, it has long been known that
migraine attacks may be precipitated by different trig-
gers, such as physical and psychological stressors [2-4].
A number of studies reported increased prevalence of
migraine in individuals with depression and anxiety
[5-10]. Comorbidity of migraine with metabolic disor-
ders, such as obesity and insulin resistance, has also
been reported [11]. In patients suffering from migraine,
increase in body weight is associated with higher* Correspondence: deryaulu@yahoo.com
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in any medium, provided the original work is pheadache frequency and severity, and with higher levels
of disability [12]. A recent study by Peterlin et al.
suggested that episodic migraine rates are increased with
obesity [13]. Population based studies also suggest that
obesity may be a risk for the progression of episodic
migraine to chronic migraine [14,15].
The neurobiological mechanisms underlying the rela-
tionship between migraine and obesity have not been
elucidated precisely. However, the known increased co-
morbidity of anxiety and depression with migraine may
be a link between migraine and altered feeding behavior
leading to obesity. It has been reported that there is
a close relationship between emotional disorders and
increased visceral fat accumulation [16]. Anxiety and
depression associated with migraine may contribute to
increased food intake in migraineurs by affecting appe-
tite regulators. The orexigenic gut hormone ghrelin is an
important modulator of energy intake [17]. It has been
reported that circulating ghrelin levels increase not only
in response to energy insufficiency but also in responseOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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levels produce anxiolytic and antidepressant-like re-
sponses. Chronic stress causes elevated ghrelin levels,
and the effects of depression and anxiety are minimized
when ghrelin levels rise [18].
In this study, we aimed to examine the role of chronic
anxiety and depression on body weight, and the modera-
ting and mediating roles of ghrelin in these relationships
in newly diagnosed, otherwise healthy, non-diabetic
migraine patients. It is possible that ghrelin mediates the
effect of depression and anxiety on body weight in migrai-
neurs. However, another possibility that has received little
attention in the literature is that ghrelin moderates the
effect of anxiety and depression on body weight in migrai-
neurs. In other words, anxiety and depression may have a
statistical interaction with ghrelin such that the effect
of ghrelin on body weight is stronger for depressed (or
anxious) migraine patients compared to non-depressed
(or non-anxious) migraine patients, and depressed (or
anxious) migraine patients who also have high levels of
ghrelin may be more vulnerable to obesity.
Methods
Three hundred seventy four consecutive migraine patients
attending for the first time the tertiary Headache Center
of Istanbul University Neurology Department (Turkey)
from January 2010 to January 2011 were screened for the
study. Migraine was diagnosed according to the ICHD-II
criteria [19]. Participants were excluded if they were: (1)
diabetic [20], had any endocrinological disease that might
interfere with insulin resistance, (2) had a history of major
psychiatric disorders, chronic renal or hepatic disease, ma-
lignancy, acute cardiovascular events, or a neurological
disease; (4) were using any medication that might interfere
with insulin resistance; or (5) were using prophylactic
antimigraine treatment. BMI is one of the medical stan-
dards for measuring adiposity and defining obesity. Body
weight (kg) and height (cm) was measured during the
study visit by a research assistant, and BMI was calculated
by dividing weight by height squared [21]. From the 374
patients screened, 63 eligible patients (7 men, 56 women;
mean age = 33.94 ± 8.85 years) participated. The patients






Age (years) 32.31 ± 8.9 33.94 ± 8.8 0.36
Gender (male/female) 9/34 7/56 0.17
BMI 23.22 ± 3.48 25.48 ± 4.55 0.01
Waist circumference 78.85 ± 9.47 83.47 ± 11.31 0.04
Female 77.79 ± 9.12 82.20 ± 11.13
Male 83.86 ± 10.21 92.71 ± 8.32and psychological examinations by an expert endocrinolo-
gist, a neurologist specialized in headache disorders, and a
clinical psychologist. According to the duration and fre-
quency of days with headache per month, headache was
further classified as episodic or chronic migraine for sup-
plemental analyses.
Our main analyses were on the data from this sample of
migraine patients. We also had a control group, which
consisted of 42 healthy volunteers (9 men, 33 women;
mean age = 32.31 ± 8.91 yrs). All participants were Turkish/
Caucasian. There were no significant differences between
the groups in smoking status or in the number of diabetes
risk factors [20]. The study was approved by the local
Ethics Committee of Istanbul University Cerrahpasa
School of Medicine and informed consent was obtained
from participants.
For supplementary analyses, the migraine patients were
further categorized as episodic versus chronic migraine
based on the definition in the ICHD-II criteria [19]. Epi-
sodic and chronic migraine patients were not significantly
different in any of the study variables (see Tables 1 and 2).
Fasting plasma ghrelin concentrations were determined by
Enzyme Immunoassay according to the manufacturer’s
guidelines (Bachem, Peninsula Laboratories, and LLC,
USA). The results are reported as pg/mL and minimum
detectable levels were 0.45 pg/mL. The mean CV was less
than 7.5%.
Depression was assessed with the Hamilton Depression
(HAM-D) scale and anxiety was assessed with the
Hamilton Anxiety (HAM-A) scale [22,23]. HAM-D scale
is a 17 item- questionnaire, and was administered by a
neurologist during a face to face interview. The minimum
score is 0 and the maximum score is 53 points. The
HAM-A probes 14 parameters and each item is scored on
a 5-point scale, ranging from 0 = not present to 4 = severe.
The scores from all 14 parameters are summed. The rec-
ommended cut-off score of 15 was used to create two
groups: (a) without anxiety, and (b) with moderate to
severe anxiety. Similarly, a cut-off score of 13 was used for
HAM-D to create two groups: (a) not depressed, and
(b) moderately to very severely depressed. Results were
similar when continuous scores were used instead of these






33.21 ± 8.7 35.50 ± 9.2 0.34
3/40 4/16 0.20
25.15 ± 4.39 26.18 ± 4.90 0.41
82.35 ± 11.26 85.94 ± 11.34 0.27
81.97 ± 11.45 82.79 ± 10.61
87.00 ± 8.66 97.00 ± 5.60











Ghrelin fasting (pgmol/l) 171.81 ± 95.1 187.31 ± 78.8 0.46 189.23 ± 77.9 183.18 ± 82.7 0.78
HAM-D 4.31 ± 4.2 11.90 ± 7.0 <0.001 11.46 ± 6.4 11.69 ± 6.8 0.68
HAM-A 5.45 ± 7.5 15.79 ± 8.8 <0.001 16.21 ± 8.5 15.66 ± 8.1 0.72
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software (version 20). All analyses were two-tailed with
α = 0.05. Mediation analyses were used to test the hy-
pothesis that ghrelin mediates the effect of depression
(or of anxiety) on BMI in migraineurs (and separately
for the control group for comparison purposes). A me-
diation requires meeting all of the following four con-
ditions: (a) The predictor (in this case depression or
anxiety) is associated with the outcome (in this case
BMI), (b) the predictor is associated with the mediator
(in this case ghrelin), (c) the mediator is associated with
the outcome while controlling for the predictor, and (d)
the effect of the predictor on the outcome becomes
non-significant (or significantly smaller) when the me-
diator is used as a control variable. These conditions
were tested using multiple regression analyses.
Moderation analyses were conducted to test for a sta-
tistical interaction between depression (or anxiety) and
ghrelin in predicting BMI [24]. This was done using
multiple regression analyses—separately for the migraine
and control groups—with BMI as the dependent vari-
able. The independent variables were ghrelin at fasting,
depression status (depressed versus not depressed), and
the interaction of these two independent variables. Simi-
lar analyses were also conducted using the dichotomized
anxiety variable instead of depression. Ghrelin scores
were centered around their mean. Age and gender were
also entered as control variables. Whenever the inter-
action term was significant, follow-up simple slope ana-
lyses were conducted to examine the relationship
between ghrelin and BMI at high and low levels of de-
pression (or anxiety).Results
The baseline characteristics of the migraine and control
groups are presented in Table 1. There were no significant
differences between the migraine and control groups in
terms of age and gender (t = .92, p = .36, and Χ2 = 2.01,
p = .17, respectively). Nevertheless, age and gender were
controlled in all analyses, since most of our analyses were
done separately for the migraine and control groups.
Table 2 presents mean HAM-A and HAM-D scores,
and ghrelin levels. HAM-A and HAM-D scores weresignificantly higher in migraineurs compared to controls
(p < .001).
Only two of the 42 control group participants were in
the depressed category (i.e., moderately to severely de-
pressed), whereas 31 of the 63 migraine patients were
moderately to severely depressed. Similarly, only three of
the 42 control group participants had moderate to se-
vere anxiety compared to 24 of the 63 migraine patients.
Neither the two depression groups nor the two anxiety
groups had significantly different BMI values for the
migraine group (F = 2.64, p = .11, and F = .66, p = .42, re-
spectively, controlling for gender and age). The control
group also did not show differences in BMI according
to depression or anxiety status (F = 1.36, p = .25, and
F = .04, p = .84, respectively, controlling for gender and
age). Thus, the first condition for mediation was not
satisfied, and therefore no claims to the mediating role
of ghrelin on the effect of depression or anxiety on BMI
could be made. Further analyses revealed that the data
did not satisfy the third and fourth conditions of me-
diation either. Furthermore, using newer, more powerful
bootstrapping techniques also did not reveal significant
indirect effects of depression or anxiety on BMI through
ghrelin. Thus, the data did not support the mediating
role of ghrelin in the relationship between depression
(or anxiety) and BMI for either the migraine or the con-
trol group.
We then tested the hypothesis that depression (or
anxiety) moderates the effect of ghrelin on BMI for
migraine patients. A moderation hypothesis means that
there is a statistical interaction between depression and
ghrelin in predicting BMI [24]. In other words, the
effect of ghrelin on BMI is different for depressed and
non-depressed participants. A regression analysis was
conducted—separately for the migraine and control
groups—with BMI serving as the outcome variable. The
independent variables were ghrelin at fasting (centered),
depression status, and the interaction of these two inde-
pendent variables. Age and gender were also entered as
control variables. This analysis revealed a significant
interaction term (B = .04, t = 2.50, p = .02) for the mi-
graine group, whereas for the control group, the inter-
action was not significant (B = .01, t = .18, p = .84). To
further probe this significant interaction for the migraine
Figure 2 Anxiety status moderates the effect of ghrelin on BMI.
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for the depressed and non-depressed migraine patients.
These analyses revealed that for depressed migraineurs
ghrelin had a positive association with BMI (B = .02,
t = 1.82, p = .07), whereas for non-depressed migraineurs
the association between ghrelin and BMI was negative
(B = −.01, t = −1.76, p = .08). Figure 1 depicts this signifi-
cant interaction for the migraine group.
Similar analyses using anxiety instead of depression
yielded parallel results (Figure 2). The interaction bet-
ween anxiety status and baseline ghrelin was significant
for the migraine group (B = .04, t = 2.59, p = .01), but not
for the control group, (B = .00 t = −.05, p = .96). Follow-
up simple slope analyses for the migraine group revealed
that for migraineurs with anxiety ghrelin had a positive
association with BMI (B = .02, t = 1.83, p = .07), whereas
for migraineurs without anxiety the association between
ghrelin and BMI was negative (B = −.02, t = −1.86,
p = .07).
Discussion
Migraine and obesity represent two major public health
problems. Moreover, both chronic migraine and obesity
are associated with increased risk of comorbidities and
have a significant impact on the health care system [25].
There is an established relationship between obesity
and headache. Data on the prevalence of migraine in
obese patients are inconclusive. However, it has been
shown that obesity is associated with an increased fre-
quency and intensity of migraine attacks [26]. It has
been reported that morbidly obese women have a high
incidence of migraine, especially migraine with aura
[27]. The same association was found in overweight ado-
lescent females who showed an almost fourfold risk for
migraine when compared with normal-weight girls [28].
In a large population-based study focusing on theFigure 1 Depression status moderates the effect of ghrelin
on BMI.relationship between BMI and episodic migraine, a total
of 30,215 participants were interviewed, and 3,791 were
diagnosed with migraine. BMI was not associated with
the prevalence of episodic migraine. However, it was as-
sociated with the frequency of headache attacks, higher
chances of aura, and severe pain [12]. In another large
study with a sample of 63,467 women (ages 45 years or
older, of which,14.5% had migraine), migraine prevalence
did not differ significantly as a function of BMI, but
severely obese women were more likely to have in-
creased headache frequency and risk of phonophobia
and photophobia [29]. Moreover, obesity is regarded as a
major risk factor for chronification of episodic migraine
in adults and children [26].
Pathophysiological mechanisms that might be respon-
sible for the association between migraine and obesity
are not fully established yet. It has been reported that
certain psychological conditions can play a role in the
migraine-obesity relationship. There is emerging evi-
dence for a possible association between stress and in-
creased risk of both headache and obesity. Studies have
shown that obesity and depression, depression and
chronic daily headache, and chronic daily headache and
obesity are linked [26]. Indeed, in a carefully conducted
study, the relationship of obesity with migraine fre-
quency and migraine-related disability was modified by
depression and anxiety, with the strongest effect ob-
served in migraineurs with both depression and anxiety.
It was concluded that the psychological comorbidities
are a common problem in migraine patients and have an
additive effect on the risk of migraine progression
[26,30]. The prevalence of major depression has been re-
ported in a number of studies to be 1.7 fold or higher
among individuals with migraine compared to non-
migraineurs [8]. In a recent study Ligthart and associates
analyzed a cohort with different types of chronic pain
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considerable part of the comorbidity of migraine and
other types of pain [6,7,31].
In the present study depression and anxiety assessed
with HAM-D and HAM-A were significantly higher in
migraine patients compared to controls. We hypothe-
sized that the psychological comorbidities in migraineurs
may be a factor leading to increased energy intake and
future obesity. In a previous study it has been reported
that there is a close relationship between increased vis-
ceral fat accumulation and emotional disorders [16]. It
has also been shown that in migraineurs, there is a ten-
dency for increased appetite [32]. Anxiety and depres-
sion in migraine may facilitate weight gain through their
interaction with central mechanisms inducing appetite.
Central regulators of energy intake may be a link bet-
ween migraine and increased energy intake. We found
that depression and anxiety were not associated with
BMI in our sample.
We tested the hypothesis that depression and anxiety
moderate the effect of ghrelin on BMI for non-diabetic
migraine patients and found support for this hypothesis.
Our results revealed a statistically significant interaction
between depression (as well as with anxiety) and ghrelin
in predicting BMI for the migraine group, but not for the
control group. That is, the effect of ghrelin on BMI was
different for depressed and non-depressed migraineurs.
For depressed migraineurs ghrelin had a positive asso-
ciation with BMI, whereas for non-depressed migraineurs
the association between ghrelin and BMI was negative.
Moreover, post-hoc exploratory analyses suggested that
the chronic migraine group is mainly responsible for the
interaction effect found. A similar interaction effect was
found for anxiety as well.
The brain-gut axis regulates appetite and maintains
energy homeostasis through communication between
the gut and the central nervous system. Dysregulation of
the brain-gut axis is associated with metabolic imbal-
ances found in eating disorders as well as in association
with stress, anxiety and depression [33]. The orexigenic
gut hormone ghrelin is an important central modulator
of energy intake [17]. Ghrelin is expressed mainly in the
arcuate nucleus of the hypothalamus although ghrelin
positive neurons are also found in the lateral hypotha-
lamus and paraventricular nucleus. Fasting causes
ghrelin to be released from the gastrointestinal tract,
and the hormone then plays a role in sending hunger
signals to the brain. It has been reported that circulating
ghrelin levels increase not only in response to energy in-
sufficiency but also in response to acute and chronic
stress [34]. The role of ghrelin in depression and anxiety
has been reported by a number of studies. In experimen-
tal studies, augmented ghrelin levels were found in mice
following chronic defeat stress, and it was suggested thatghrelin might be involved in the defense against stress
induced depression and anxiety. Ghrelin infusion into
the lateral ventricle produced an anxiolytic like effect
and inhibition of ghrelin induced an increase in depres-
sion and anxiety like behaviors in rats.
Human studies on ghrelin and stress suggest the co-
ordinating role of ghrelin on behavioral response to
stress by modulating energy intake. In one study, pa-
tients suffering from major depression had lower plasma
ghrelin levels and antidepressant effects were reported
following ghrelin administration [35]. Chronic stress
causes ghrelin levels to go up and behaviors associated
with depression and anxiety decrease when ghrelin levels
rise. An unfortunate side effect, however, is increased
food intake and body weight [36]. In mice, the stress-
induced rises in ghrelin lead to overeating and increased
body weight, suggesting a mechanism for the increased
prevalence of weight-related issues observed in humans
with chronic stress and depression [18].
The diurnal pattern of ghrelin secretion plays an import-
ant role in meal initiation. In a previous study, Cummings
and colleagues have sought to determine whether a single,
conveniently obtainable plasma ghrelin value could serve
as a surrogate for the integrated 24-h AUC ghrelin value
in human subjects [36]. They reported that ghrelin levels
rose nearly two-fold shortly before each meal and fall to
trough levels within 1 h after eating, a diurnal profile that
is consistent with a physiological role for ghrelin in initia-
ting individual meals. They concluded that overnight fas-
ting ghrelin levels measured early in the morning and 1st
hour after breakfast both have a very high correlation with
24-h AUC values of the hormone (r = 0.873, P = 0.0004).
We measured overnight fasting ghrelin levels. Therefore,
we cannot make any conclusions about postprandial
changes in ghrelin levels. However, we can assume
that fasting ghrelin levels reflected the diurnal ghrelin
dynamics.
Our findings did not support the mediating role of
ghrelin in the relationship between anxiety (or depres-
sion) and BMI for either the migraine or the control
group. However, our data revealed a significant inter-
action between ghrelin and anxiety and depression, such
that migraine patients with depression (or anxiety) as
well as high levels of ghrelin had higher BMI.
One limitation of this study is that ghrelin levels were
assessed only in the beginning of headache treatment.
Changes in ghrelin could also be examined after headache
and/or depression treatment. In our control group, only
two participants had depression and only three had an-
xiety. It should be noted, however, results were very simi-
lar, and conclusions the same, when we used continuous
scores of symptom severity for depression and anxiety in-
stead of using binary variables for depression and anxiety
status. Furthermore, the important contribution of our
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depression (or anxiety) on BMI for the migraine group,
which included a substantial number of patients with de-
pression and anxiety.
The groups did not differ statistically in terms of gen-
der distribution. Nevertheless, we statistically controlled
for the effects of gender, since our sample size was not
large. The headache and control groups differed in BMI,
and we do not know whether or not this affected the re-
sults in comparing the headache group with the control
group. However, as mentioned earlier, the important
contribution of our data is in highlighting the interactive
effect of ghrelin and depression (or anxiety) on BMI for
the migraine group.
Conclusion
Obesity should be kept under control as it is a cause of
cardiovascular risk in migraine patients. Migraineurs
should be motivated to maintain a normal weight for
height and age or decrease it if overweight or obese.
Reaching this goal will require sticking to sensible diets
and receiving behavioral support. The management of
anxiety and depression associated with migraine should
be regarded as a part of migraine treatment. The use of
migraine preventive medications that are weight-neutral
or that are associated with weight loss in those who are
overweight or obese may be recommended.
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